Disease awareness in hemophilia: impact on therapeutic adherence and clinical outcomes
Revista Hemostasia y Trombosis · 30.10.2026 · 3 (1)
DOI: 10.24875/rht.m26000086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Hemostasia y Trombosis, online erschienen am 30.10.2026. Verfasst von Agustina M. Petracco und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Hemophilia is an inherited bleeding disorder that requires multidisciplinary management to reduce long-term complications.Disease awareness may influence treatment adherence and clinical outcomes.
Objective
To analyze the relationship between disease awareness and adherence to prophylactic therapy in patients with hemophilia.Material and methods: A review of assessment tools and strategies addressing psychosocial, educational, and economic barriers to adherence was conducted.
Results
Higher disease awareness was associated with improved adherence, reduced bleeding episodes, and better preservation of joint function.
Conclusions
Disease awareness is a key determinant of adherence in patients with hemophilia.Interventions that enhance patient self-management may improve long-term health outcomes.
Zitieren
APA
Petracco, A. M., Magliaro, D. A., Cinara, L. C., Pasquero, M. V., & Davoli, M. R. (2026). Disease awareness in hemophilia: impact on therapeutic adherence and clinical outcomes. Revista Hemostasia y Trombosis, 3(1). https://doi.org/10.24875/rht.m26000086
Vancouver
Petracco AM, Magliaro DA, Cinara LC, Pasquero MV, Davoli MR. Disease awareness in hemophilia: impact on therapeutic adherence and clinical outcomes. Revista Hemostasia y Trombosis. 2026;3(1). doi:10.24875/rht.m26000086
BibTeX
@article{Petracco2026,
author = {Petracco, Agustina M. and Magliaro, Daniel A. and Cinara, Luis C. and Pasquero, Mariela V. and Davoli, Mauro R.},
title = {Disease awareness in hemophilia: impact on therapeutic adherence and clinical outcomes},
journal = {Revista Hemostasia y Trombosis},
year = {2026},
volume = {3},
number = {1},
doi = {10.24875/rht.m26000086}
}
EUVIMED